Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma
- 28 February 2006
- journal article
- research article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 96 (2) , 316-326
- https://doi.org/10.1016/s1081-1206(10)61242-2
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004
- Allergic rhinitis, rhinosinusitis, and asthma: one airway diseaseImmunology and Allergy Clinics of North America, 2004
- Rhinitis and asthma: Evidence for respiratory system integrationJournal of Allergy and Clinical Immunology, 2003
- The Burden of Asthma in the United StatesAmerican Journal of Respiratory and Critical Care Medicine, 2002
- The link between allergic rhinitis and allergic asthma: A prospective population‐based study. The Copenhagen Allergy StudyAllergy, 2002
- Treating the allergic patient: think globally, treat globallyAllergy, 2002
- Epidemiologic evidence for asthma and rhinitis comorbidityJournal of Allergy and Clinical Immunology, 2000
- The role of allergy in the development of asthmaNature, 1999
- Allergic rhinitis in Rochester, Minnesota residents with asthma: Frequency and impact on health care chargesJournal of Allergy and Clinical Immunology, 1999
- Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to AllergensNew England Journal of Medicine, 1989